# **2010 Interim Results**

SFAF meeting August 31, 2010



## SUMMARY

- 1. 'Hybrid' growth
- 2. Strong interim results
- 3. Focus on two strategic pillars:
  - Innovation through R&D
  - Potential for external growth
  - Questions and answers

Our business: animals. Our advantage: people.



# Highlights of the 1<sup>st</sup> half of 2010

- Expanding world market
- Hybrid growth
  - Internal growth
  - External growth



### **Continued growth in the animal health market**

 According to Vetnosis, in first half 2010 the animal health market grew by 10.4% over the previous period

By species*	Companion animals	Cattle	Pigs
Global trend for the first half	+8.0%	+9.7%	+15.6%

By therapeutic area*	Anti-infective	Other
Global trend for the first half	+10.0%	+17.0%


By geographical region*	North	Western	Asia/
	America	Europe	Pacific
Global trend for the first half	+9.5%	+7.1%	+15.3%

\*Source: Vetnosis, August 2010



### Vétoquinol ranks 4<sup>th</sup> worldwide in terms of growth in USD

Vétoquinol, again one of the five fastest growing laboratories






### Vétoquinol: key figures for the first half of 2010





### Pursuit of 'hybrid' growth in business




• 15.1% revenues growth for the 1<sup>st</sup> half




### Increased organic growth

Organic growth between 4 and 5%, exceeding our economic model's projections





### Our portfolio remains well balanced



#### Trends by species

0	Companion animals:	+11.0%


- Livestock: +19.1%
  - Cattle: +16.0%
  - Pigs: +16.5%

#### Observations

- Strong performance for companion animals
- Improved position in livestock following acquisitions in Italy and India



### **Growth in strategic areas**



Trends by therapeutic area


0	Anti-infective:	+14.5%
0	Pain and inflammation :	+7.9%
0	Cardiology/nephrology:	+14.9%
0	Other:	+18.6%

#### Observations

- Strong performance in all three strategic areas
- Gradual re-balancing of strategic therapeutic areas



### Strong progress in new territories



#### **Regional trends**

0	Europe:	+4.2%
0	Americas:	+22.9%

Asia/Pacific: +125.5% 0

#### **Observations**

- Strong growth in Asia/Pacific and the 0 Americas
- Large contribution in Italy 0
- Steady sales growth in India Ο

23%



### **Update on recent acquisitions**

- Italy
  - Acquired in December 2008
  - $\circ$   $\;$  Now reaping the initial fruits of the acquisition

#### India

- Acquired in August 2009
- Integration completed in June 2010
  - Renewal of distribution contracts
  - Physical separation of relations with Wockhardt





REE! 20% EXTRA

TILOX



### Dynamic 1<sup>st</sup> half of 2010

#### Launch of Surolan<sup>®</sup> in the United States

- o Anti-infective agent for the treatment of external otitis in dogs
- Well received by American animal health professionals

#### Preparations for new product launches in 2011

- Product registrations under way
- o Marketing and sales efforts

#### Exclusive distribution contract: Zylkene<sup>®</sup>

- First contract for the distribution of Zylkene in the Americas (United States, Canada and Mexico)
- An innovative product in a promising market segment

#### Boreve-d project

- Vétoquinol is participating in a project organised by the SIMV to raise awareness of the need to treat pain in cattle
- Vétoquinol sells three related products: Tolfine<sup>®</sup>, Lurocaïne<sup>®</sup> and Calmagine<sup>®</sup>



### **Consolidated financial statements for 06/30/2010**

- Income statement
- Cash flow statement
- Financial structure
- Working capital requirements



### **2010 interim income statement**

In € million	06/30/2010	% of revenues	06/30/2009	% of revenues	Δ%
Revenues	138.0		119.9		+15.1%
Margin on purchases consumed	91.0	65.9	80.6	67.2	+12.9%
External costs	(30.1)	(21.8)	(26.1)	(21.8)	+15.2%
Personnel costs	(40.2)	(29.1)	(35.4)	(29.5)	+13.6%
Taxes and duties	(1.9)	(1.3)	(2.1)	(1.7)	-9.7%
Other income and expenses	2.0	1.5	2.2	1.8	-7.4%
Depreciation, amortisation and provisions	(5.0)	(3.6)	(5.4)	(4.5)	-8.2%
Operating profit from current operations	15.9	11.6	13.8	11.5	+15.3%



### 2010 interim income statement (continued)

in € million	30/06/2010	% of revenues	30/06/2009	% of revenues	Δ%
Operating profit from current operations	15.9	11.6	13.8	11.5	+15.3%
Operating profit	15.9	11.6	13.8	11.5	+15.3%
Financial income	0.5	0.4	(1.7)	(1.4)	NS
Income before taxes	16.5	11.9	12.2	10.1	+35.4%
Income tax expenses	(4.9)	(3.5)	(2.9)	(2.4)	NS
Net profit attributable to parent company shareholders	11.6	8.4	9.3	7.7	+25.2%
Net cash flows provided (used) by operating activities	16.0		16.3		-1.8%

\* Operating profit + depreciation, amortisation and provisions – income tax expenses



### **Cash flow statement**

in € million	06/30/2010	06/30/2009
Cash flow generated by operating activities	15.1	18.4
Cash flow used by investment	(3.3)	(5.1)
Cash flow used by financing	(24.6)	20.3
Impact of changes in exchange rates	0.8	0.3
Change in cash and cash equivalents	(12.0)	33.9
Cash flow before cost of net financial debt and income tax	24.3	19.4



### **Sound financial structure**



	06/30/2010	12/31/2009	06/30/2009
Gearing	4.0%	9.5%	2.4%



### **Working capital requirements**

in € million	06/30/2010	06/30/2009
Inventories	47.4	43.9
Trade receivables and related accounts	52.8	42.6
Trade payables and related accounts	(52.9)	(44.0)
Other elements of WCR	(1.7)	0.9
Working capital requirements	45.6	43.4



### Working capital requirements


holding business scope and exchange rates constant

in € million	06/30/2010 at constant scope and exchange rates	06/30/2009
Inventories	42.7	43.9
Trade receivables and related accounts	44.2	42.6
Trade payables and related accounts	(45.3)	(44.0)
Other elements of WCR	(1.6)	0.9
Working capital requirements	40.0	43.4

Effective control of WCR



### Share price trends



- Vétoquinol shares
  - Market capitalisation: €310 million
  - Share price up by **23.3%** in the first 8 months of the year

Our business: animals. Our advantage: people.


# Strategy and outlook

Innovative R&D

Strong potential for extenrnal growth



### Developing a new medication: a long and unpredictable process...



R&D



### ... and averages 7 years

1 y			year 2		years 5	5 years	7 years
Objective	Identification of new molecules or substances capable of preventing, curing or relieving a disease		Research to improve the properties and action of the molecules identified by the research		Testing the new molecule on animals	Obtain administrative approval from the health authorities to market the medication	
Molecules	Selection of the most active molecules	Selection of the molecules with the best effectiveness to tolerance	Selection of the most active molecules	Selection of the best molecules for animal testing	Decision to file a registratio n request	plac produc ma	sation to e the t on the rket MM)
	100 candidate projects				5 medications		


AMM, 3 parts: > Quality > Safety > Effectiveness



R&D




### A team of experts in the development of medications





### Vétoquinol's R&D portfolio





### An active programme of external growth

- External growth: the other engine for growth at Vétoquinol
- Three areas of current interest:
  - o 'Pro-active' candidates
  - o 'Reactive' candidates
  - Divestitures resulting from mega mergers




### A real potential for growth

- Priority always given to strategic targets
- Financing capacity of approximately €200 million
- Potential for revenue growth on the order of €100 million (> 30%)



### In conclusion, strong performance

- Satisfactory 1<sup>st</sup> half
  - o Dynamic 'hybrid' growth
- Encouraging outlook
  - New product launches
  - Projects for external growth





### Calendar

- October 19, 2010 3<sup>rd</sup> quarter 2010 revenues
- January 25, 2011 2010 annual revenues





### Our business: animals. Our advantage: people.